Visgeneer Inc. (TPEX:4197)
Taiwan · Delayed Price · Currency is TWD 10.55
-1.55 (-12.81%)
Sep 11, 2026, 1:52 PM CST
Visgeneer Revenue
Visgeneer had revenue of 81.61M TWD in the half year ending June 30, 2026, with 77.59% growth. This brings the company's revenue in the last twelve months to 170.72M, up 6.86% year-over-year. In the year 2025, Visgeneer had annual revenue of 179.06M with 54.68% growth.
Revenue (ttm)
170.72M
Revenue Growth
+6.86%
P/S Ratio
1.87
Revenue / Employee
1.74M
Employees
98
Market Cap
318.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 179.06M | 63.30M | 54.68% |
| Dec 31, 2024 | 115.76M | -32.24M | -21.78% |
| Dec 31, 2023 | 147.99M | -9.97M | -6.31% |
| Dec 31, 2022 | 157.96M | -7.32M | -4.43% |
| Dec 31, 2021 | 165.29M | -10.68M | -6.07% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| BioLASCO Taiwan | 258.04M |
| RBC Bioscience | 220.60M |
| Lukas Biomedical | 170.01M |
| Feng Chi Biotech | 156.99M |
| Vectorite Biomedical | 54.81M |
| Neith | 31.84M |
| SynCore Biotechnology Co.,Ltd | 26.24M |